Weekly Quick Hits (BioHealth Capital Region) – Week of March 20, 2023 By Sarah Ellinwood, Alex Keown, and Mark TerryMarch 24, 2023 Funding, Awards and Collaborations MacroGenics Earns $15 Million [….]
At the 2023 Society of Toxicology Annual Meeting in Nashville, Baltimore-based MyMD presented preclinical data that showed MyMD-1, an oral next-generation TNF-α inhibitor, significantly reduced signs of arthritis. Data showed MYMD-1 reduced histopathological changes and the severity of standard arthritis clinical trial measures, the company announced.
Here is some of the latest life science news out of the BioHealth Capital Region
MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to developing novel therapies for age-related diseases, autoimmune and inflammatory conditions, today announced the publication of results from a Phase 1 study of oral tumor necrosis factor-alpha (TNF-α) inhibitor, MYMD-1® (Isomyosamine), in peer-reviewed journal, Drug Research. The randomized, double-blind, placebo-controlled study, intended to evaluate the safety, tolerability, and pharmacokinetic profile of MYMD-1 in healthy adults, found that single daily doses for 3 days and multiple daily doses for 6 days were safe and well tolerated in healthy subjects. The study used single daily doses of 150 mg, 300 mg, and 450 mg, respectively, and multiple daily doses of 600 mg. There were no new or unexpected safety findings and no clinically relevantor severe adverse events reported.
MyMD Pharmaceuticals Announces Publication of Phase 1 Data for oral TNF-alpha Inhibitor MYMD-1® in Peer-Reviewed Journal Drug Research
